Compare TYRA & NVGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TYRA | NVGS |
|---|---|---|
| Founded | 2018 | 1997 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2021 | 2013 |
| Metric | TYRA | NVGS |
|---|---|---|
| Price | $19.70 | $20.80 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 6 |
| Target Price | ★ $47.45 | $26.08 |
| AVG Volume (30 Days) | ★ 577.7K | 377.0K |
| Earning Date | 11-10-2026 | 11-03-2026 |
| Dividend Yield | N/A | ★ 1.52% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $13.06 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.94 | $17.12 |
| 52 Week High | $40.65 | $25.48 |
| Indicator | TYRA | NVGS |
|---|---|---|
| Relative Strength Index (RSI) | 41.01 | 44.25 |
| Support Level | $18.46 | $19.84 |
| Resistance Level | $22.69 | $22.69 |
| Average True Range (ATR) | 1.19 | 0.71 |
| MACD | -0.10 | 0.12 |
| Stochastic Oscillator | 12.33 | 55.70 |
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Navigator Holdings Ltd owns and operates liquefied gas carriers, which include a fleet of handysize liquefied gas carriers. The company also owns a share in an ethylene export marine terminal at Morgan's Point, Texas on the Houston Ship Channel (the Ethylene Export Terminal) through a joint venture (the Export Terminal Joint Venture). The company plays a vital role in the globalised liquefied gas supply chain, providing gas transportation solutions for energy companies, industrial users, and commodity traders.